NLRP3 inflammasome pathway is involved in olfactory bulb pathological alteration induced by MPTP
暂无分享,去创建一个
[1] Houeto Jean-Luc. [Parkinson's disease]. , 2022, La Revue du praticien.
[2] R. Niranjan. Recent advances in the mechanisms of neuroinflammation and their roles in neurodegeneration , 2018, Neurochemistry International.
[3] R. Melki. Alpha-synuclein and the prion hypothesis in Parkinson's disease. , 2018, Revue neurologique.
[4] K. Schroder,et al. Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice , 2018, Science Translational Medicine.
[5] B. Christensen,et al. NLRP3 expression in mesencephalic neurons and characterization of a rare NLRP3 polymorphism associated with decreased risk of Parkinson’s disease , 2018, npj Parkinson's Disease.
[6] Ming Lu,et al. Inhibition of the hepatic Nlrp3 protects dopaminergic neurons via attenuating systemic inflammation in a MPTP/p mouse model of Parkinson’s disease , 2018, Journal of Neuroinflammation.
[7] N. Chen,et al. NLRP3 inflammasome activation in the thymus of MPTP-induced Parkinsonian mouse model. , 2018, Toxicology letters.
[8] Xiao-Liang Liu,et al. Damage to dopaminergic neurons by oxidative stress in Parkinson's disease (Review). , 2018, International journal of molecular medicine.
[9] N. Ghanem,et al. “Till Death Do Us Part”: A Potential Irreversible Link Between Aberrant Cell Cycle Control and Neurodegeneration in the Adult Olfactory Bulb , 2018, Front. Neurosci..
[10] N. Chen,et al. A Novel Bibenzyl Compound (20C) Protects Mice from 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine/Probenecid Toxicity by Regulating the α-Synuclein–Related Inflammatory Response , 2017, The Journal of Pharmacology and Experimental Therapeutics.
[11] Li Wang,et al. Editor’s Highlight: Nlrp3 Is Required for Inflammatory Changes and Nigral Cell Loss Resulting From Chronic Intragastric Rotenone Exposure in Mice , 2017, Toxicological sciences : an official journal of the Society of Toxicology.
[12] N. Chen,et al. Amyloidogenic proteins associated with neurodegenerative diseases activate the NLRP3 inflammasome , 2017, International immunopharmacology.
[13] K. Ray Chaudhuri,et al. Non-motor features of Parkinson disease , 2017, Nature Reviews Neuroscience.
[14] K. Chaudhuri,et al. Non-motor features of Parkinson disease , 2017, Nature Reviews Neuroscience.
[15] R. Ortega,et al. Amyotrophic lateral sclerosis-like superoxide dismutase 1 proteinopathy is associated with neuronal loss in Parkinson’s disease brain , 2017, Acta Neuropathologica.
[16] Rishi Pal,et al. The potential role of neuroinflammation and transcription factors in Parkinson disease , 2017, Dialogues in clinical neuroscience.
[17] D. Wesson,et al. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases , 2016, Neurobiology of Disease.
[18] M. Srivastava,et al. Potential therapeutic targets for inflammation in toll-like receptor 4 (TLR4)-mediated signaling pathways. , 2016, International immunopharmacology.
[19] R. Ransohoff. How neuroinflammation contributes to neurodegeneration , 2016, Science.
[20] N. Chen,et al. Environment-contact administration of rotenone: A new rodent model of Parkinson’s disease , 2015, Behavioural Brain Research.
[21] Jing Deng,et al. NOS1-derived nitric oxide promotes NF-κB transcriptional activity through inhibition of suppressor of cytokine signaling-1 , 2015, The Journal of experimental medicine.
[22] A. Lang,et al. Parkinson's disease , 2015, The Lancet.
[23] F. Shi,et al. NALP3 inflammasome activation in protein misfolding diseases. , 2015, Life sciences.
[24] R. Jaenisch,et al. Parkinson-causing α-synuclein missense mutations shift native tetramers to monomers as a mechanism for disease initiation , 2015, Nature Communications.
[25] W. Oertel,et al. A new dopaminergic nigro-olfactory projection , 2015, Acta Neuropathologica.
[26] Jiahuai Han,et al. Impeding the interaction between Nur77 and p38 reduces LPS-induced inflammation. , 2015, Nature chemical biology.
[27] Lei Liu,et al. Dopamine Controls Systemic Inflammation through Inhibition of NLRP3 Inflammasome , 2015, Cell.
[28] C. Power,et al. Inflammasomes in the CNS , 2014, Nature Reviews Neuroscience.
[29] P. Brundin,et al. Transfer of human α-synuclein from the olfactory bulb to interconnected brain regions in mice , 2013, Acta Neuropathologica.
[30] N. H. Rod,et al. Psychosocial risk factors, pre‐motor symptoms and first‐time hospitalization with Parkinson's disease: a prospective cohort study , 2013, European journal of neurology.
[31] M. Luquin,et al. Reduced cholinergic olfactory centrifugal inputs in patients with neurodegenerative disorders and MPTP-treated monkeys , 2013, Acta Neuropathologica.
[32] M. Brucale,et al. Triggering of Inflammasome by Aggregated α–Synuclein, an Inflammatory Response in Synucleinopathies , 2013, PloS one.
[33] C. Olanow,et al. Parkinson's Disease and Alpha Synuclein: Is Parkinson's Disease a Prion‐Like Disorder? , 2013, Movement disorders : official journal of the Movement Disorder Society.
[34] A. Lees,et al. Meta-Analysis of Early Nonmotor Features and Risk Factors for Parkinson Disease , 2012, Annals of neurology.
[35] D. Golenbock,et al. NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1β and neuronal toxicity , 2012, Cellular and Molecular Life Sciences.
[36] G. Núñez,et al. Sensing and reacting to microbes through the inflammasomes , 2012, Nature Immunology.
[37] S. Masters,et al. Disease-associated amyloid and misfolded protein aggregates activate the inflammasome. , 2011, Trends in molecular medicine.
[38] S. Hayley,et al. Inflammatory Mechanisms of Neurodegeneration in Toxin-Based Models of Parkinson's Disease , 2010, Parkinson's disease.
[39] J. Kordower,et al. Age-related changes in glial cells of dopamine midbrain subregions in rhesus monkeys , 2010, Neurobiology of Aging.
[40] F. Martinon. Signaling by ROS drives inflammasome activation , 2010, European journal of immunology.
[41] Thomas Gasser,et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria , 2009, The Lancet Neurology.
[42] A. Petrie,et al. Regional differences in the severity of Lewy body pathology across the olfactory cortex , 2009, Neuroscience Letters.
[43] F. Martinon,et al. The inflammasomes: guardians of the body. , 2009, Annual review of immunology.
[44] K. Jellinger. Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders , 2009, Acta Neuropathologica.
[45] J. Trojanowski,et al. Neuroinflammation and Oxidation/Nitration of α-Synuclein Linked to Dopaminergic Neurodegeneration , 2008, The Journal of Neuroscience.
[46] N. Bohnen,et al. Diagnostic performance of clinical motor and non‐motor tests of Parkinson disease: a matched case–control study , 2008, European journal of neurology.
[47] S. Akira,et al. Pathogen Recognition and Innate Immunity , 2006, Cell.
[48] Smita Patel,et al. Intravesicular Localization and Exocytosis of α-Synuclein and its Aggregates , 2005, The Journal of Neuroscience.
[49] H. Braak,et al. Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.
[50] J. Bertin,et al. PYPAF7, a Novel PYRIN-containing Apaf1-like Protein That Regulates Activation of NF-κB and Caspase-1-dependent Cytokine Processing* , 2002, The Journal of Biological Chemistry.
[51] F. Martinon,et al. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. , 2002, Molecular cell.
[52] D. Schaid,et al. Anxiety disorders and depressive disorders preceding Parkinson's disease: A case‐control study , 2000, Movement disorders : official journal of the Movement Disorder Society.
[53] A. Bowie,et al. The Interleukin-1 Receptor/toll-like Receptor Superfamily: Signal Generators for Pro-inflammatory Interleukins and Microbial Products , 2022 .
[54] T. Roth,et al. Waking up to sleep episodes in Parkinson's Disease , 2000, Movement disorders : official journal of the Movement Disorder Society.
[55] M. L. Schmidt,et al. α-Synuclein in Lewy bodies , 1997, Nature.
[56] P. Lansbury,et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. , 1996, Biochemistry.
[57] W. Gibb,et al. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. , 1991, Journal of neurology, neurosurgery, and psychiatry.
[58] Roger Barker,et al. Environmental toxins and Parkinson's disease , 1989, Trends in Neurosciences.
[59] W. Gibb,et al. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.
[60] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[61] N. Perkins,et al. Integrating cell-signalling pathways with NF-κB and IKK function , 2007, Nature Reviews Molecular Cell Biology.
[62] N. Perkins,et al. Integrating cell-signalling pathways with NF-kappaB and IKK function. , 2007, Nature reviews. Molecular cell biology.
[63] S. Akira,et al. Toll-like receptors. , 2003, Annual review of immunology.
[64] A. Baldwin,et al. The NF-kappa B and I kappa B proteins: new discoveries and insights. , 1996, Annual review of immunology.
[65] A. Baldwin,et al. THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .